The metabolic activity assessed by 18F-FDG PET and its correlation with tumor immune status and prognosis in advanced biliary tract cancer patients treated with 1L GemCis plus durvalumab +/-tremelimumab.

Authors

null

Jeesun Yoon

Medical Oncology, Seoul National University Hospital, Seoul, South Korea

Jeesun Yoon , Hyunpil Sung , Kyung-Hun Lee , Jin Won Kim , Dae-Won Lee , Tae-Yong Kim , Ju-Hee Bang , Ah-Rong Nam , Kyoung-Seok Oh , Jae-Min Kim , Yoojin Jeong , Sea Young Choo , Hyo Jung Kim , Su In Lee , Gi Jeong Cheon , Do-Youn Oh

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Hepatobiliary Cancer - Advanced/Metastatic Disease

Clinical Trial Registration Number

NCT03046862

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 4092)

DOI

10.1200/JCO.2023.41.16_suppl.4092

Abstract #

4092

Poster Bd #

413

Abstract Disclosures

Similar Posters

First Author: Mohamed Bouattour

Poster

2024 ASCO Gastrointestinal Cancers Symposium

Prognostic effects of co-occurring <i>TP53</i> and <i>KRAS</i> aberrations in patients with advanced biliary tract cancer.

Prognostic effects of co-occurring TP53 and KRAS aberrations in patients with advanced biliary tract cancer.

First Author: Taro Shibuki